HEALTH-RELATED QUALITY-OF-LIFE (HRQOL) IN ADULTS AND CHILDREN WITH NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMA (NF1-PN) TREATED WITH MIRDAMETINIB: PIVOTAL, PHASE 2B RENEU TRIAL

Overview

cited authors

Babovic-Vuksanovic, Dusica; Hirbe, Angela; Moertel, Christopher; Shuhaiber, Hans; Sidhu, Alpa; Bielamowicz, Kevin; Viskochil, David; Bell, Timothy; Weber, Michael; Langseth, Abraham; Lokku, Armend; Weintraub, Lauren; Hajjar, Fouad; Foreman, Nick; Gershon, Timothy; McNall-Knapp, Rene

Publication Date

November 11, 2024

webpage

Web of Science

published in

NEURO-ONCOLOGY Journal

301 E Princeton St., Orlando, FL 32804 | FH.RAS@AdventHealth.com | 407-200-2901

The information on this website is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. Please consult your physician before undertaking any form of medical treatment and/or adopting any exercise program or dietary guidelines. If you think you may have a medical emergency, call your physician or 911 immediately. AdventHealth Research Institute reserves the right to add, remove or edit content on this page at its sole discretion.